Leah Backhus1, Jonathon Sargent2, Aaron Cheng3, Steven Zeliadt4, Douglas Wood3, Michael Mulligan3. 1. Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Wash. Electronic address: lbackhus@u.washington.edu. 2. University of Washington School of Medicine, Seattle, Wash. 3. Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Wash. 4. Department of Health Services, University of Washington School of Public Health, Seattle, Wash.
Abstract
OBJECTIVES: Lung volume reduction surgery (LVRS) provides palliation and improved quality of life in select patients with end-stage chronic obstructive pulmonary disease (COPD). The effect of previous LVRS on lung transplant outcomes has been inadequately studied. We report our experience in the largest single institution series of these combined procedures. METHODS: The records of 472 patients with COPD undergoing lung transplantation or LVRS between 1995 and 2010 were reviewed. Outcomes of patients undergoing transplant after LVRS were compared with outcomes of patients undergoing transplant or LVRS alone. Survival was compared using log-rank tests and the Kaplan-Meier method. RESULTS: Demographics, comorbidities, and spirometry were similar at the time of transplantation. Patients who had undergone lung transplant after LVRS had longer transplant operative times (mean 4.4 vs 5.6 hours; P = .020) and greater hospital length of stay (mean 17.6 vs 29.1 days; P = .005). Thirty-day mortality and major morbidity were similar. Posttransplant survival was reduced for transplant after LVRS (median, 49 months; 95% confidence interval [CI], 16, 85 months) compared with transplant alone (median, 96 months; 95% CI, 82, 106 months; P = .008). The composite benefit of combined procedures, defined as bridge from LVRS to transplant of 55 months and posttransplant survival of 49 months (total 104 months), was comparable with survival of patients undergoing either procedure alone. CONCLUSIONS: Lung transplant after LVRS leads to minimal additional perioperative risk. The reduced posttransplant survival in patients undergoing combined procedures is in contradistinction to reports from other smaller series. When determining the best surgical treatment for patients with more severe disease, the benefit of LVRS before transplant should be weighed against the consequence of reduced posttransplant survival. Published by Mosby, Inc.
OBJECTIVES: Lung volume reduction surgery (LVRS) provides palliation and improved quality of life in select patients with end-stage chronic obstructive pulmonary disease (COPD). The effect of previous LVRS on lung transplant outcomes has been inadequately studied. We report our experience in the largest single institution series of these combined procedures. METHODS: The records of 472 patients with COPD undergoing lung transplantation or LVRS between 1995 and 2010 were reviewed. Outcomes of patients undergoing transplant after LVRS were compared with outcomes of patients undergoing transplant or LVRS alone. Survival was compared using log-rank tests and the Kaplan-Meier method. RESULTS: Demographics, comorbidities, and spirometry were similar at the time of transplantation. Patients who had undergone lung transplant after LVRS had longer transplant operative times (mean 4.4 vs 5.6 hours; P = .020) and greater hospital length of stay (mean 17.6 vs 29.1 days; P = .005). Thirty-day mortality and major morbidity were similar. Posttransplant survival was reduced for transplant after LVRS (median, 49 months; 95% confidence interval [CI], 16, 85 months) compared with transplant alone (median, 96 months; 95% CI, 82, 106 months; P = .008). The composite benefit of combined procedures, defined as bridge from LVRS to transplant of 55 months and posttransplant survival of 49 months (total 104 months), was comparable with survival of patients undergoing either procedure alone. CONCLUSIONS: Lung transplant after LVRS leads to minimal additional perioperative risk. The reduced posttransplant survival in patients undergoing combined procedures is in contradistinction to reports from other smaller series. When determining the best surgical treatment for patients with more severe disease, the benefit of LVRS before transplant should be weighed against the consequence of reduced posttransplant survival. Published by Mosby, Inc.
Authors: Danil V Makarov; Elaine Y C Hu; Dawn Walter; R Scott Braithwaite; Scott Sherman; Heather T Gold; Xiao-Hua Andrew Zhou; Cary P Gross; Steven B Zeliadt Journal: Health Serv Res Date: 2015-09-30 Impact factor: 3.402
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Alexis Slama; Laurens J Ceulemans; Celia Hedderich; Panja M Boehm; Jan Van Slambrouck; Stefan Schwarz; Christelle M Vandervelde; Markus Kamler; Peter Jaksch; Dirk Van Raemdonck; Konrad Hoetzenecker; Clemens Aigner Journal: Transpl Int Date: 2022-04-14 Impact factor: 3.842
Authors: Danil V Makarov; Shannon Ciprut; Dawn Walter; Matthew Kelly; Heather T Gold; Xiao-Hua Zhou; Scott E Sherman; Ronald Scott Braithwaite; Cary Gross; Steven Zeliadt Journal: JAMA Netw Open Date: 2018-08-03